Literature DB >> 6174171

Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.

S Miyazaki, K Miura, Y Kasai, K Abe, K Yoshinaga.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6174171      PMCID: PMC1495917          DOI: 10.1136/bmj.284.6312.310

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  5 in total

1.  Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.

Authors:  J A Lopez-Ovejero; S D Saal; W A D'Angelo; J S Cheigh; K H Stenzel; J H Laragh
Journal:  N Engl J Med       Date:  1979-06-21       Impact factor: 91.245

2.  Inhibitory effects of -guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin.

Authors:  M Muramatu; S Fujii
Journal:  Biochim Biophys Acta       Date:  1972-04-07

3.  Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.

Authors:  O A Carretero; S Miyazaki; A G Scicli
Journal:  Hypertension       Date:  1981 Jan-Feb       Impact factor: 10.190

4.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

5.  Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.

Authors:  A Overlack; K O Stumpe; M Kühnert; R Kolloch; C Ressel; I Heck; F Krück
Journal:  Klin Wochenschr       Date:  1981-01-15
  5 in total
  6 in total

Review 1.  Raynaud's phenomenon: its relevance to scleroderma.

Authors:  J J Belch
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 2.  Pathogenesis and treatment of Raynaud's phenomenon.

Authors:  J D Coffman
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 3.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

4.  Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.

Authors:  V F Challenor; D G Waller; R A Hayward; M J Griffin; O S Roath
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

5.  Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.

Authors:  B Santos Ramos; M J Piña Vera; E Carvajal Gragera; M Atienza Fernández
Journal:  Pharm World Sci       Date:  1993-10-15

Review 6.  Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Authors:  V F Challenor
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.